Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,160 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,029 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (561)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04121273 | GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC | unknown | Phase 1 | 20 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 3, 2021 | clinicaltrials |
| NCT04042805 | Sintilimab Combined With Lenvatinib in Local Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 36 | Baocai XingOTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02786342 | Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib(INNOVATE) | unknown | — | 160 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04773769 | Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas | unknown | N/A | 54 | Auxilio Mutuo Cancer CenterOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT04170179 | Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic Metastasis | unknown | Phase 2 | 25 | Sun Yat-sen UniversityOTHER | 1 | Feb 23, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04229355 | DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma | unknown | Phase 3 | 90 | Guangxi Medical UniversityOTHER | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04708483 | DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria | unknown | N/A | 100 | HyperfusionINDUSTRY | 1 | Feb 9, 2021 | clinicaltrials |
| NCT04741165 | Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 72 | Taizhou Hanzhong biomedical co. LTDINDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03941626 | Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies | unknown | Phase 1 / Phase 2 | 50 | Shenzhen BinDeBio Ltd.INDUSTRY | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04738188 | Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; | unknown | N/A | 226 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04739501 | Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors | unknown | — | 100 | Assiut UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT04733521 | A Phase 1/2 Study of SC-43 in Combination With Cisplatin | unknown | Phase 1 / Phase 2 | 100 | RaND BiosciencesINDUSTRY | 0 | Feb 2, 2021 | clinicaltrials |
| NCT03146637 | Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer | unknown | Phase 2 | 80 | Benhealth Biopharmaceutical (Shenzhen) Co., Ltd.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04730388 | ATEZOLIZUMAB - BEVACIZUMAB in the Treatment Hepatocellular Carcinoma Inoperable or(HEPATOFIT) | unknown | — | 100 | University Hospital, BrestOTHER | 0 | Jan 29, 2021 | clinicaltrials |
| NCT04731220 | A Questionnaire Survey for Biliary Tract Cancers | unknown | — | 12,000 | Kyungpook National University Chilgok HospitalOTHER | 1 | Jan 29, 2021 | clinicaltrials |
| NCT03794440 | A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | unknown | Phase 2 / Phase 3 | 595 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04665362 | IIT Study of M1-c6v1 Combined With SHR-1210 and Apatinib in Patients With HCC | unknown | Phase 1 | 10 | Liang PengOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04705194 | Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging(HEPARIM) | unknown | — | 134 | University of LeedsOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT04107324 | ARAPS Study on Accelerated Liver Regeneration(ARAPS) | unknown | N/A | 30 | University of AarhusOTHER | 1 | Jan 15, 2021 | clinicaltrials |
| NCT04479527 | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 34 | Peking University Cancer Hospital & InstituteOTHER | 0 | Jan 14, 2021 | clinicaltrials |
| NCT04687163 | Sorafenib or Lenvatinib Plus HAIC of 130 mg/m² Oxaliplatin, and 5-fu vs Sorafenib or Lenvatinib Plus HAIC of 85mg/m² Oxaliplatin, and 5-fu for Unresectable Advanced HCC: a Randomised Phase 3 Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04692051 | A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer | unknown | Phase 2 | 100 | Huazhong University of Science and TechnologyOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT04183088 | Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 125 | National Taiwan University HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT04668976 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | unknown | Phase 2 | 100 | Benaroya Research InstituteOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04677088 | TCR-Redirected T Cell Treatment in Patients With Recurrent HBV-related Hepatocellular Carcinoma Post Liver Transplantation | unknown | Phase 1 | 7 | Xiaoshun HeOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT04640116 | TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites | unknown | N/A | 30 | Sun Yat-sen UniversityOTHER | 0 | Dec 19, 2020 | clinicaltrials |
| NCT04667351 | HAIC of Oxaliplatin, and 2400 mg/m² 5-fu vs HAIC of Oxaliplatin, and 1200 mg/m² 5-fu for Unresectable HCC: a Randomised Phase 3 Non-inferiority Trial | unknown | Phase 3 | 400 | Sun Yat-sen UniversityOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03475966 | Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program | unknown | N/A | 60 | McGill University Health Centre/Research Institute of the McGill University Health CentreOTHER | 1 | Dec 8, 2020 | clinicaltrials |
| NCT03896958 | The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)(PIONEER) | unknown | — | 1,000 | SpeciCareINDUSTRY | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04653701 | Safety and Efficacy of DEB-TACE Performed With a Novel Reflux-control Microcatheter in Patients With HCC | unknown | — | 30 | Juan José Ciampi DopazoOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04652492 | Tislelizumab in Combination With TACE in Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 72 | Zhongda HospitalOTHER | 1 | Dec 3, 2020 | clinicaltrials |
| NCT04619342 | Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in the Treatment of Hepatocellular Carcinoma (HCC) With Type III Portal Vein Tumor Thrombus (PVTT) | unknown | N/A | 98 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03898921 | RFA vs. SBRT for Small HCC | unknown | Phase 3 | 270 | Sun Yat-sen UniversityOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03766633 | Accuracy of the LiverVision® Semi-automated Liver Volumetry Software(LiverVision) | unknown | — | 108 | Royal Free Hospital NHS Foundation TrustOTHER | 3 | Nov 20, 2020 | clinicaltrials |
| NCT04633382 | ENHANCED RECOVERY AFTER BILIARY TRACT SURGERY | unknown | N/A | 50 | Vitebsk State Medical UniversityOTHER | 0 | Nov 19, 2020 | clinicaltrials |
| NCT04627363 | HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 0 | Nov 13, 2020 | clinicaltrials |
| NCT04317248 | "Cocktail" Therapy for Hepatitis B Related Hepatocellular Carcinoma | unknown | Phase 2 | 600 | Yuehua HuangOTHER | 1 | Oct 29, 2020 | clinicaltrials |
| NCT02046356 | Recurrence Risk Factors of Early-Stage Hepatocellular Carcinoma After Radio Frequency Ablation | unknown | — | 139 | Yunhua TanOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04181931 | Neo-TACE-HAIC for PVTT-HCC(NeoconceptC) | unknown | N/A | 320 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT04424043 | Neo-TACE-HAIC for BCLC B Stage HCC(NeoconceptB) | unknown | N/A | 280 | Sun Yat-sen UniversityOTHER | 1 | Oct 26, 2020 | clinicaltrials |
| NCT03645980 | DKN-01 Inhibition in Advanced Liver Cancer | unknown | Phase 1 / Phase 2 | 70 | Johannes Gutenberg University MainzOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT04597970 | TACE Plus HAIC With Oxaliplatin and Raltitrexed for BCLC Stage C HCC(OXRI) | unknown | Phase 2 | 66 | Peking University Cancer Hospital & InstituteOTHER | 0 | Oct 22, 2020 | clinicaltrials |
| NCT04076631 | Surgical Stages of Liver Cirrhosis In Patients With Hepatocellular Carcinoma | unknown | — | 1,000 | Chen XiaopingOTHER | 1 | Oct 12, 2020 | clinicaltrials |
| NCT03302403 | Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors | unknown | N/A | 18 | Kang YUOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT03383796 | Comparing Three Dimension Laparoscopic Versus Open Surgery for Perihiliar Cholangiocarcinoma | unknown | N/A | 30 | Tongji HospitalOTHER | 1 | Oct 8, 2020 | clinicaltrials |
| NCT04454762 | A Study to Evaluate the Safety, Tolerability and Efficacy of Cabozantinib in Patients With Hepatocellular Carcinoma and Impaired Liver Function(CaboCHILD) | unknown | Phase 2 | 20 | Johannes Gutenberg University MainzOTHER | 1 | Oct 5, 2020 | clinicaltrials |
| NCT04550663 | NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors | unknown | Phase 1 | 10 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 23, 2020 | clinicaltrials |
| NCT04560751 | TACE Combined With Lenvatinib for Unresectable Hepatocellular Carcinoma (Prolong) | unknown | — | 300 | Zhejiang Cancer HospitalOTHER | 0 | Sep 23, 2020 | clinicaltrials |
| NCT04443322 | Durvalumab and Lenvatinib in Participants With Locally Advanced and Metastatic Hepatocellular Carcinoma ( Dulect2020-1 )(Dulect2020-1) | unknown | N/A | 20 | RenJi HospitalOTHER | 1 | Sep 22, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Mar 3, 2021source: clinicaltrials